FDA Panel Says Columbia Labs' (CBRX) Data on Preterm Birth Gel Isn't Sufficient (WPI)
Tweet
Share
E-mailGet Alerts CBRX Hot Sheet
Join SI Premium – FREE
FDA panel votes 13-4 data on Columbia Labs' (Nasdaq: CBRX) is not sufficent on preterm birth gel.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Hyperfine wins FDA clearance for updated portable MRI software
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
